These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23012303)

  • 21. Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.
    Bilgin B; Şendur MA; Hızal M; Akıncı MB; Dede DŞ; Yalçın B
    Future Oncol; 2019 Jan; 15(2):105-107. PubMed ID: 30484708
    [No Abstract]   [Full Text] [Related]  

  • 22. Biology matters: the clinical impact of single-receptor discordance on breast cancer.
    Farolfi A; Ibrahim T; Scarpi E; Amadori D
    Ann Oncol; 2013 Mar; 24(3):851. PubMed ID: 23417916
    [No Abstract]   [Full Text] [Related]  

  • 23. Triple-negative breast cancer.
    Chacón RD; Costanzo MV
    Breast Cancer Res; 2010; 12 Suppl 2(Suppl 2):S3. PubMed ID: 21050424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple-negative breast cancer: what the radiologist needs to know.
    Whitman GJ; Albarracin CT; Gonzalez-Angulo AM
    Semin Roentgenol; 2011 Jan; 46(1):26-39. PubMed ID: 21134526
    [No Abstract]   [Full Text] [Related]  

  • 25. Targeting triple negative breast cancer: is p53 the answer?
    Turner N; Moretti E; Siclari O; Migliaccio I; Santarpia L; D'Incalci M; Piccolo S; Veronesi A; Zambelli A; Del Sal G; Di Leo A
    Cancer Treat Rev; 2013 Aug; 39(5):541-50. PubMed ID: 23321033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular stratification of triple-negative breast cancers.
    Perou CM
    Oncologist; 2010; 15 Suppl 5():39-48. PubMed ID: 21138954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis.
    Liu N; Wang X; Sheng X
    Curr Opin Obstet Gynecol; 2011 Feb; 23(1):19-23. PubMed ID: 21150601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come.
    Mittendorf EA; King TA
    Ann Surg Oncol; 2019 May; 26(5):1173-1175. PubMed ID: 30798446
    [No Abstract]   [Full Text] [Related]  

  • 29. Triple negative breast cancer: breast cancer research in evolution.
    Eng-Wong J; Hunsberger S; Zujewski JA
    Breast Dis; 2010; 32(1-2):1-4. PubMed ID: 21778576
    [No Abstract]   [Full Text] [Related]  

  • 30. Hormone receptor-positive breast cancer: the known and the unknown.
    Dawood S; Gonzalez-Angulo AM
    Oncology (Williston Park); 2012 Aug; 26(8):700-1. PubMed ID: 22957402
    [No Abstract]   [Full Text] [Related]  

  • 31. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
    Kurebayashi J
    Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [How to optimize the clinical therapeutic protocol for triple-positive breast cancer].
    Wang N; Wang YJ
    Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):241-3. PubMed ID: 20510070
    [No Abstract]   [Full Text] [Related]  

  • 33. Neoadjuvant treatments for triple-negative breast cancer (TNBC).
    von Minckwitz G; Martin M
    Ann Oncol; 2012 Aug; 23 Suppl 6():vi35-9. PubMed ID: 23012300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The ethnic profile of triple-negative breast cancer.
    Cleator SJ; Palmieri C; Coombes CR
    Onkologie; 2008 Nov; 31(11):580-2. PubMed ID: 19145089
    [No Abstract]   [Full Text] [Related]  

  • 35. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?
    Burness ML; Grushko TA; Olopade OI
    Cancer J; 2010; 16(1):23-32. PubMed ID: 20164687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estrogen, progesterone, and Her-2/neu receptor expression discrepancy in primary tumors and in-breast relapse in patients with breast cancer.
    Mavrova R; Radosa J; Schmitt K; Bohle RM; Rody A; Solomayer EF; Juhasz-Böess I
    Breast J; 2014; 20(3):322-4. PubMed ID: 24720257
    [No Abstract]   [Full Text] [Related]  

  • 38. The natural history of hormone receptor-positive breast cancer: attempting to decipher an intriguing concept.
    Nagaraj G; Ellis MJ; Ma CX
    Oncology (Williston Park); 2012 Aug; 26(8):696-7, 700. PubMed ID: 22957401
    [No Abstract]   [Full Text] [Related]  

  • 39. Targeting triple-negative breast cancer: optimising therapeutic outcomes.
    Gelmon K; Dent R; Mackey JR; Laing K; McLeod D; Verma S
    Ann Oncol; 2012 Sep; 23(9):2223-2234. PubMed ID: 22517820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Directed therapy of subtypes of triple-negative breast cancer.
    Carey LA
    Oncologist; 2010; 15 Suppl 5():49-56. PubMed ID: 21138955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.